|
End-of-day quote
Shanghai S.E.
2026-08-18
|
5-day change | 1st Jan Change | ||
| 72.58 CNY | -2.21% |
|
-2.54% | +6.63% |
| 08-11 | Gan & Lee Pharmaceuticals Grants Menarini Licensing Rights to Develop Diabetes Drug in Europe; Shares Jump 10% | MT |
| 07-13 | Gan & Lee Pharmaceuticals Gets China Nod for Breast Cancer Drug Trial | MT |
| Market Cap | 43.2B 6.41B 5.53B 5.21B 4.73B 8.9B 614B 9.03B 61.06B 23.93B 307B 24.05B 23.53B 1,023B | P/E 2026 * |
31.2x | P/E 2027 * | 26.7x |
|---|---|---|---|---|---|
| Enterprise Value | 39.99B 5.93B 5.12B 4.82B 4.38B 8.24B 568B 8.36B 56.53B 22.15B 284B 22.26B 21.78B 947B | EV / Sales 2026 * |
8.46x | EV / Sales 2027 * | 7.02x |
| Free-Float |
57.83% | Yield 2026 * |
0.33% | Yield 2027 * | 0.39% |
| 1 day | -2.21% | ||
| 1 week | -2.54% | ||
| Current month | +5.60% | ||
| 1 month | +12.93% | ||
| 3 months | +32.88% | ||
| 6 months | +11.68% | ||
| Current year | +6.63% |
| 1 week | 72.11 |  | 79.79 |
| 1 month | 62.9 | | 79.99 |
| Current year | 51.51 | | 79.99 |
| 1 year | 51.51 | | 82.25 |
| 3 years | 32.1 | | 82.25 |
| 5 years | 30.53 | | 85.49 |
| 10 years | 30.53 | | 204.41 |
| Manager | Title | Age | Since |
|---|---|---|---|
Wei Chen
CEO | Chief Executive Officer | 46 | 2025-05-29 |
Qi Wang
DFI | Director of Finance/CFO | 44 | 2026-03-08 |
Ting Jia
CTO | Chief Tech/Sci/R&D Officer | - | 2026-03-08 |
| Director | Title | Age | Since |
|---|---|---|---|
Fu Ming Xu
BRD | Director/Board Member | 41 | 2025-11-16 |
Zhong Ru Gan
CHM | Chairman | 78 | 1998-06-16 |
Kai Du
BRD | Director/Board Member | 49 | 2009-12-31 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -2.21% | -2.54% | +14.10% | +75.48% | 6.41B | |
| +0.65% | +1.66% | +41.18% | -0.27% | 80.91B | |
| -1.10% | -4.85% | -3.14% | +29.15% | 50.13B | |
| +0.88% | -3.93% | +11.18% | +169.94% | 47.97B | |
| +4.52% | +19.16% | -26.85% | -38.18% | 53.62B | |
| +1.63% | +4.25% | +56.39% | -18.61% | 31.41B | |
| -2.33% | +3.95% | +124.14% | -38.04% | 25.14B | |
| -0.02% | +1.98% | +45.40% | +92.80% | 25.03B | |
| +1.91% | +3.09% | +0.77% | +216.21% | 21.45B | |
| +1.49% | +5.26% | +65.34% | +127.30% | 16.93B | |
| Average | +0.54% | -0.32% | +32.85% | +61.58% | 35.9B | |
| Weighted average by Cap. | +0.91% | -0.18% | +26.50% | +43.46% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 4.73B 701M 605M 570M 518M 974M 67.15B 988M 6.68B 2.62B 33.59B 2.63B 2.57B 112B | 5.53B 820M 709M 667M 606M 1.14B 78.61B 1.16B 7.82B 3.06B 39.31B 3.08B 3.01B 131B |
| Net income | 1.39B 206M 178M 168M 152M 287M 19.78B 291M 1.97B 771M 9.89B 775M 758M 32.95B | 1.63B 241M 208M 196M 178M 335M 23.12B 340M 2.3B 902M 11.56B 906M 886M 38.52B |
| Net Debt | -3.21B -476M -411M -387M -352M -661M -45.61B -671M -4.54B -1.78B -22.81B -1.79B -1.75B -75.99B | -4.36B -647M -559M -526M -478M -898M -61.97B -912M -6.17B -2.42B -30.99B -2.43B -2.38B -103B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-08-18 | CN¥72.58 | -2.21% | 13,369,957 |
| 26-08-17 | CN¥74.22 | -1.01% | 15,841,695 |
| 26-08-14 | CN¥74.98 | -3.23% | 23,418,182 |
| 26-08-13 | CN¥77.48 | +0.36% | 30,369,486 |
| 26-08-12 | CN¥77.20 | +3.67% | 38,834,227 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- 603087 Stock
Select your edition
All financial news and data tailored to specific country editions
